Use of low dose rVSV-ZEBOV: Safety issues in a Swiss cohort

The Lancet Infectious Diseases

Volumn 15, Issue 10, 2015, Pages 1117-1119

  Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; GLYCOPROTEIN; RECOMBINANT VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS-BASED CANDIDATE VACCINE; UNCLASSIFIED DRUG;

ARTHRITIS; COMORBIDITY; DERMATITIS; DRUG SAFETY; EBOLAVIRUS; HUMAN; IMMUNOCOMPETENCE; JOINT ASPIRATION; LOW DRUG DOSE; MACULOPAPULAR RASH; NOTE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SKIN BIOPSY; SWISS; SYNOVIAL FLUID; VACCINATION; VESICULAR STOMATITIS; ADVERSE EFFECTS; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MALE; PROCEDURES;

EBOLA VACCINES; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; VACCINATION;

EID: 84942197960     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00222-4     Document Type: Note

References (8)

1. Huttner A, Dayer J, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015; published online Aug 4. http://dx.doi.org/10.1016/S1473-3099(15)00154-1.
2. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine-preliminary report. N Engl J Med 2015; published April 1. DOI:. http://dx.doi.org/10.1056/NEJMoa1414216.
3. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe-preliminary report. N Engl J Med 2015; published online April 1. DOI:. http://dx.doi.org/10.1056/NEJMoa1502924.
4. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13:1267-1277.
5. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
6. Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015, 385:1545-1554.
7. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine -preliminary report. N Engl J Med 2014; published online Nov 26. DOI:. http://dx.doi.org/10.1056/NEJMoa1410863.
8. Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015, 211:549-557.